Ricardo awarded over 18.9million USD to deliver additional ABS/ESC retrofit kits to US Army
The United States Army has awarded Ricardo’s Defense business unit, located in Michigan, over 18.9million USD to deliver additional Antilock Brake System/Electronic Stability Control (ABS/ESC) retrofit kits to improve the safety of operation of the US Army’s High Mobility Multipurpose Wheeled Vehicle (HMMWV).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005571/en/
Ricardo Awarded Over 18.9 million USD to Deliver Additional ABS/ESC Retrofit Kits to US Army (Photo: Business Wire)
In addition to those retrofit kits Ricardo has previously delivered, this contract award will improve safety on fielded vehicles in the US Army’s enduring HMMWV fleet. Additionally, more than 7,000 new production or recapitalized HMMWV vehicles have been delivered to the US Army with Ricardo’s integrated ABS/ESC technology following the Army’s mandate of the Ricardo system on all new production HMMWVs. In 2019, the Army provisioned Ricardo’s ABS/ESC retrofit kit into the national stock system for application of vehicles produced prior to 2019 that are slated to remain in the Army’s enduring fleet through 2040.
Chet Gryczan, President of Ricardo Defense said: “Ricardo is committed to providing our customers with mission critical, innovative, integrated solutions that deliver capability to the soldier. This award demonstrates that Ricardo can solve tough challenges for legacy systems that require a future-looking integrated solution. Consistent with our core values of sustainable, safe, and smart mobility, the successful deployment of Ricardo’s ABS/ESC safety critical system ensures the safety of soldiers and operators remain at the forefront of every training and operational mission. We are extremely proud to support the US Army’s objective ensuring that soldier safety remains a top priority throughout each mission.”
The Ricardo developed ABS/ESC retrofit system encompasses a complete solution integrated into the HMMWV architecture including antilock braking, electronic stability control, active rollover protection, traction control, and improved brake calipers, pads, and rotors. The Ricardo system additionally introduces a crashworthy steering column and a modern electronic network to the vehicle and leverages low-cost, proven components specifically designed for the arduous requirements of military application. From the beginning, Ricardo designed the system for ease of upgrade to the existing fleet to minimize HMMWV lifecycle cost to US taxpayers.
Ends
Ricardo Defense Inc, is the business entity within Ricardo plc that works on classified safety and defence contracts for the US DoD and it therefore operates as a separate entity governed by a Special Security Agreement (SSA). Ricardo Defense Inc provides solutions to meet the challenges faced by defence customers in the integration of complex and diverse systems specialising in taking innovative technologies from science to real-world deployment.
About Ricardo
Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com
Ricardo Defense Inc, is the business entity within Ricardo plc that works on classified safety and defence contracts for the US DoD and it therefore operates as a separate entity governed by a Special Security Agreement (SSA). Ricardo Defense Inc provides solutions to meet the challenges faced by defence customers in the integration of complex and diverse systems specialising in taking innovative technologies from science to real-world deployment.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005571/en/
Contact information
Media contacts:
Kathryn Bellamy
Group Senior Communications Manager
Ricardo plc
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824
Kathryn Caulfield
Communications Manager
Ricardo Defense
Email: kathryn.caulfield@ricardodefense.com
Telephone: +1 (586) 899-7668
Cell: +1(248) 602-5159
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom